Profitability
Weight: 20%
F
0
- 5yr Avg ROIC -7.3%
- Operating Margin Trend -19.42 pp/yr
VNDA
Vanda Pharmaceuticals Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 2 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 19.2 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
17
- 5yr Avg ROE -12.1%
- 5yr Share-Count CAGR 0.9%
Growth Quality
Weight: 15%
F
16
- 5yr Revenue CAGR -5.3%
- 5yr EPS CAGR -72.6%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 15%
D
34
- 5yr FCF Margin -3.4%
- 5yr FCF/NI Conversion 3.95x
Balance Sheet
Weight: 20%
D-
30
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score -0.23
Stability
Weight: 15%
F
22
- EPS Volatility (σ/μ) 1.22
- Piotroski F-Score 2
- Negative-Revenue Years (5) 2/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 2 gurus held; 1 added; 1 full exit.
- Holders
- 1 -1
- Avg Δ position
- +162.9%
- New buys
- 0
- Full exits
- 1